Health
GC Pharma sticks to plasma therapy study despite global trial failures – Korea Biomedical Review
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing…
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing results in phase 3 clinical trials.
Takeda, one of the co-leaders of the CoVig-19 Plasma Alliance, said Wednesday that the group has completed the phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trials and decided to end the year-long collaboration as it did not meet the endpoint in the study.
…
-
Noosa News17 hours agoYoung voices shape Sunshine Coast’s future
-
Business17 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News16 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News14 hours agoCopperString transmission line projected to cost almost $14b amid massive blowout